CAU
ARQT icon

Caxton Associates (UK)’s Arcutis Biotherapeutics ARQT Stock Holding History

Caxton Associates (UK)’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$220K Buy
+8,374
New +$195K ﹤0.01% 696
2026
Q1 		– Sell
-8,718
Closed -$253K – 779
2025
Q4 		$253K Buy
+8,718
New +$223K 0.01% 653

Other funds holding ARQT

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Caxton Associates (UK)'s ARQT Position: Q2 2026 in Review

Caxton Associates (UK) opened a new position in Arcutis Biotherapeutics (ARQT) in Q2 2026: 8,374 shares worth $220K. The stake represents ﹤0.01% of the portfolio and ranks #696 among its holdings. This is a return to the name: Caxton Associates (UK) previously reported a position in ARQT as recently as Q4 2025.

Caxton Associates (UK) first reported a position in ARQT in Q4 2025 and has held it in 2 quarters since. The position peaked at $253K in Q4 2025. 272 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

  • Caxton Associates (UK) held 8,374 shares of Arcutis Biotherapeutics worth $220K as of Q2 2026.
  • Arcutis Biotherapeutics was a new Caxton Associates (UK) position in Q2 2026.
  • Arcutis Biotherapeutics made up ﹤0.01% of Caxton Associates (UK)'s portfolio in Q2 2026, its #696 holding.
  • Caxton Associates (UK) first reported a position in Arcutis Biotherapeutics in Q4 2025 and has held it in 2 quarters since.
  • Caxton Associates (UK)'s Arcutis Biotherapeutics position peaked at $253K in Q4 2025.
  • 272 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on Caxton Associates (UK)'s 13F filing for Q2 2026, filed 14 Aug 2026.